Search - tctmd.com

Displaying 1 - 20 of 45

Sort: Relevancy | Date

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2024

Shelley Wood

April 30, 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

Shelley Wood

April 01, 2024

News Daily News

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

L.A. McKeown

February 23, 2024

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

News Daily News

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

L.A. McKeown

August 31, 2023

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Caitlin E. Cox

August 30, 2023

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Shelley Wood

May 30, 2023

News Daily News

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

Shelley Wood

May 09, 2023

News Daily News

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

Todd Neale

March 15, 2023

News Opinion CV Team Dispatch

January 2023 News Roundup

L.A. McKeown

January 16, 2023

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2022

Caitlin E. Cox

December 01, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

Advertisement

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

TCTMD’s Top 10 Most Popular Stories for April 2024

What’s Going to Be Hot at ACC 2024

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

January 2023 News Roundup

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

TCTMD’s Top 10 Most Popular Stories for November 2022

What’s Going to Be Hot at ESC 2022?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content